Department of Cardiothoracic Surgery, Weill Cornell Medicine, New York, NY, USA.
Department of Nuclear Medicine, Mount Sinai Hospital, New York, NY, USA.
Eur J Cardiothorac Surg. 2024 Aug 2;66(2). doi: 10.1093/ejcts/ezae310.
Clinical trials that are terminated prematurely may generate incomplete and potentially biased data and the reasons for premature trials termination are poorly understood. Our objective was to describe the incidence of premature trial termination and identify factors associated with it.
We performed a systematic search on ClinicalTrials.gov to identify all cardiac surgery trials from 1991 to 2023. Trials that were terminated prematurely were identified. Factors independently associated with premature termination were identified using multivariable logistic regression analysis.
A total of 746 clinical trials were included; of them 577 were completed and 169 (22.6%) were terminated prematurely. Most of the trials originated from North America [294 (39.4%)], Europe [264 (35.4%)] or Asia [141 (18.9%)]. Fourteen of the trials terminated prematurely (8.3%) were phase 1, 75 (44.4%) phase 2, 49 (29.0%) phase 3 and 31 (18.3%) phase 4. Fifty (29.6%) trials were terminated because of slow recruitment, 20 (11.8%) because of sponsor decision and 12 (7.1%) because of lack of funding. Left ventricular assist device trials [odds ratio (OR) 3.65, 95% confidence interval (CI) (1.65-8.00) P = 0.001], valve surgery trials [OR 4.30, 95% CI (2.33-8.00) P < 0.001], aortic surgery trials [OR 2.86 95% CI (1.22-6.43) P = 0.012], phase 2 [OR 3.02, 95% CI (1.31-7.93) P = 0.015] and phase 4 trials [OR 3.62, 95% CI (1.43-10.23) P = 0.010] were at higher risk of premature termination while trials performed in Asia [OR 0.18, 95% CI (0.07-0.39) P ≤ 0.001] and Europe [OR 0.49, 95% CI (0.30-0.80) P = 0.004] were less likely to be terminated prematurely.
Slow recruitment is the most common reason for premature termination of cardiac surgery trials. Trials on left ventricular assist device, valve surgery, aortic surgery, phase 2 trials and phase 4 trials are more likely to be terminated, while trials conducted in Asia and Europe are less likely to be terminated prematurely.
提前终止的临床试验可能会产生不完整且潜在有偏的数据,且提前终止临床试验的原因尚未得到充分了解。我们的目的是描述提前终止试验的发生率,并确定与之相关的因素。
我们在 ClinicalTrials.gov 上进行了系统检索,以确定 1991 年至 2023 年所有心脏手术试验。确定提前终止的试验。使用多变量逻辑回归分析确定与提前终止独立相关的因素。
共纳入 746 项临床试验;其中 577 项完成,169 项(22.6%)提前终止。大多数试验来自北美[294(39.4%)]、欧洲[264(35.4%)]或亚洲[141(18.9%)]。14 项提前终止(8.3%)的试验为 1 期,75 项(44.4%)为 2 期,49 项(29.0%)为 3 期,31 项(18.3%)为 4 期。50 项(29.6%)试验因招募缓慢而终止,20 项(11.8%)因赞助商决定而终止,12 项(7.1%)因资金不足而终止。左心室辅助装置试验[比值比(OR)3.65,95%置信区间(CI)(1.65-8.00)P=0.001]、瓣膜手术试验[OR 4.30,95%CI(2.33-8.00)P<0.001]、主动脉手术试验[OR 2.86,95%CI(1.22-6.43)P=0.012]、2 期试验[OR 3.02,95%CI(1.31-7.93)P=0.015]和 4 期试验[OR 3.62,95%CI(1.43-10.23)P=0.010]提前终止的风险更高,而在亚洲[OR 0.18,95%CI(0.07-0.39)P≤0.001]和欧洲[OR 0.49,95%CI(0.30-0.80)P=0.004]进行的试验提前终止的可能性较小。
招募缓慢是心脏手术试验提前终止的最常见原因。左心室辅助装置、瓣膜手术、主动脉手术、2 期试验和 4 期试验的试验更有可能提前终止,而在亚洲和欧洲进行的试验提前终止的可能性较小。